One of the hotter stocks in big healthcare just now is pharmacy chain mainstay CVS Health (NYSE: CVS). The company's shares have raced more than 18% higher year to date, comparing favorably to the benchmark S&P 500 index's sub-13% rise.
And, according to most ****** ysts tracking the stock, the stock's not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.
Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus ****** yst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.
#continue #pharmacy
And, according to most ****** ysts tracking the stock, the stock's not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.
Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus ****** yst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.
#continue #pharmacy
1 day ago
